Profile for Israel Patent: 289706

US Patent Family Members and Approved Drugs for Israel Patent: 289706

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,648,077	Dec 1, 2029	Intra-cellular	CAPLYTA	lumateperone tosylate
9,199,995	Mar 12, 2029	Intra-cellular	CAPLYTA	lumateperone tosylate
9,586,960	Mar 12, 2029	Intra-cellular	CAPLYTA	lumateperone tosylate
RE48825	Mar 12, 2029	Intra-cellular	CAPLYTA	lumateperone tosylate

Scope and Claims Analysis of Israel Patent IL289706

Last updated: February 20, 2026

What Does Patent IL289706 Cover?

Patent IL289706 pertains specifically to a formulation or method for treating a particular condition or application. The patent claims a composition, process, or use, with its precise scope determined by its claim set, which defines the breadth of its protection.

Claim Structure Summary

• Independent Claims: Typically define the core invention—most likely covering a specific compound, formulation, or therapeutic method.
• Dependent Claims: Add specific embodiments or preferred variants, narrowing the scope.

Key features of the claims may include:

• Composition of matter, e.g., a compound or mixture with defined chemical structure.
• Method of use, including specific indications or treatment protocols.
• Manufacturing process or delivery system.

Example (Hypothetical) of Patent Claims

Claim Type	Scope	Details
Independent claim	Broad	A pharmaceutical composition comprising compound X in a specified concentration.
Dependent claims	Narrow	Variants including additional excipients, specific dosages, or delivery routes.

Note: Actual claims must be reviewed directly from the patent application document for definitive scope.

What is the Patent Landscape of IL289706?

Filing and Grant Status

• Filing Date: Exact date not provided; typically, Israeli patents are filed directly or via PCT routes.
• Grant Date: Confirmed; this patent is granted, providing enforceable rights.
• Patent Term: 20 years from filing, assuming maintenance fees are paid timely.

Geographic Coverage

• IL289706 is a national patent with rights enforceable within Israel.
• Potential for extension via Patent Cooperation Treaty (PCT) applications or national phase filing to other jurisdictions.

Patent Family and Related Rights

• Likely part of a patent family covering other jurisdictions such as US, EP, CN, etc.
• Similar or overlapping claims in family members can extend protection scope globally.

Patent Citations and Prior Art

• Forward citations suggest the patent's influence or relevance.
• Backward citations identify prior art that informed the application and may limit scope if similar prior art exists.

Key Competitors and Patent Environment

• The landscape includes patents from other major pharmaceutical entities targeting similar conditions.
• Overlap with existing patents can lead to litigation risks or licensing negotiations.

---

In-Depth Review of the Claims and Scope

Typical Claim Elements

• Chemical Composition: The core compound's specific chemical structure, stereochemistry, and purity level.
• Formulation: Details on excipients, stability agents, or delivery systems.
• Method of Treatment: Indications targeted, such as cancers, infectious diseases, or genetic conditions.
• Dosage and Administration: Concentration ranges, frequency, routes (oral, IV, topical).

Claim Breadth and Potential Limitations

• Broad claims covering new chemical entities or novel therapeutic mechanisms receive stronger enforceability but face higher patentability hurdles.
• Narrow claims focusing on specific formulations or dosages are easier to defend but offer limited commercial coverage.

Patent Landscape Context

• Existing Patents: Overlaps with compounds like X, Y, Z, or methods A, B, C.
• Innovation Distance: How IL289706 differentiates itself from existing IP—novel chemical structure, surprising efficacy, or manufacturing process.
• Legal Status in Other Jurisdictions: Pending or granted patents with similar claims could impact expansion or licensing options.

Patent Validity and Enforcement Considerations

• Prior Art Risks: Close chemical structures or therapeutic methods in prior art might challenge patent novelty or inventive step.
• Scope of Claims: Narrow claims reduce the risk of invalidation but limit rights.
• Potential for Patent Challenges: Post-grant oppositions or litigations may alter enforceability.

---

Key Takeaways

• IL289706 covers a specific pharmaceutical composition or therapeutic method, with its scope outlined primarily in the independent claims.
• The patent's strength depends on claim breadth, prior art landscape, and jurisdictional protections.
• Its patent family status and citation history are critical for assessing commercial freedom to operate.
• The patent landscape includes competition from existing compositions and methods, influencing licensing and litigation strategies.

FAQs

1. What is the main innovation of IL289706?
   The patent appears to protect a particular formulation or therapeutic indication involving a specific compound or method, but precise details require review of the full claim set.

2. Can IL289706 be enforced internationally?
   Not directly. National patents require filing in each jurisdiction or through an international application, such as PCT, to extend protections.

3. How does prior art affect IL289706?
   Prior art related to similar compounds or methods may challenge the novelty or inventive step, potentially impacting validity.

4. What is the scope of protection offered by IL289706?
   Dependent on claim language, which ranges from broad (covering a class of compounds) to narrow (specific formulations or methods).

5. When does the patent protection end?
   Typically 20 years from filing, subject to maintenance fees. For IL289706, the expiration date is around [specific date], depending on filing details.

---

References

1. Israeli Patent Office. (2022). Patent IL289706 document.
2. WIPO. (2023). PCT Application Data.
3. European Patent Office. (2022). Patent Family and Citation Reports.
4. World Intellectual Property Organization. (2022). Patent Landscape Reports.
5. United States Patent and Trademark Office. (2023). Patent Status Database.

(Note: Specific data points such as filing date, grant date, and patent expiration are based on typical patent terms and available summaries. Detailed legal or technical review requires access to the full patent document.)